Salomon Azoulay, an officer of MBX Biosciences, Inc., filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 373 shares of common stock on NASDAQ.
Key Highlights
- Proposed seller: Salomon Azoulay, identified as an officer of MBX Biosciences, Inc.
- Shares proposed for sale: 373 shares of common stock, with an aggregate market value of $20,126.78.
- Acquisition date and nature: The 373 shares were acquired on November 2, 2026, via restricted stock vesting from the issuer, with compensation as the nature of payment.
- Approximate date of sale: November 4, 2026, through Fidelity Brokerage Services LLC.
- Shares outstanding: 48,160,096 shares of common stock outstanding, according to the filing.
- Prior sales: Azoulay sold 370 shares of common stock on August 4, 2026, for gross proceeds of $24,335.97, within the past three months.
- Stated purpose: The filing notes the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
Azoulay's Proposed Share Sale at MBX Biosciences: Filing Details
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Salomon Azoulay, an officer of MBX Biosciences, Inc. (NASDAQ:MBX), proposed to sell 373 shares of the company's common stock through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. The aggregate market value of the proposed sale was listed as $20,126.78. MBX Biosciences is headquartered at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
The filing discloses that the 373 shares subject to the proposed sale were acquired on November 2, 2026, through a restricted stock vesting transaction from the issuer. The nature of payment is described as compensation. The filing's remarks state that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," indicating a portion of the proceeds is intended to satisfy tax liabilities associated with the equity award.
The filing also reports that, within the three months preceding this notice, Azoulay sold 370 shares of common stock on August 4, 2026, generating gross proceeds of $24,335.97. As of the filing, the total shares of MBX Biosciences common stock outstanding were reported as 48,160,096. The notice was dated November 4, 2026, and was signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Salomon Azoulay.
What Was Disclosed
MBX Biosciences officer Salomon Azoulay filed a Form 144 on November 4, 2026, disclosing a proposed sale of 373 common shares valued at $20,126.78, acquired via restricted stock vesting on November 2, 2026, partly to cover a tax obligation from a vested equity award.



Please wait processing your request...